Koninklijke Philips (PHIA) Q3 2024 earnings summary

Executive summary

• Achieved strong profitability and margin improvement in Q3 2024, with flat sales as growth outside China offset deteriorating demand in China.

• Updated full-year outlook reflects intensified uncertainties in China, with adjusted EBITDA/EBITA margin expected at the upper end of the range (~11.5%).

• Remain ahead of the three-year plan on sales, margin, and cash, focusing on operational execution, innovation, and sustainable value creation.

• Net income increased to €181 million from €90 million in Q3 2023, mainly due to higher gross margin and lower Respironics field action costs.

• Free cash flow was €22 million in Q3, impacted by working capital outflows; full-year guidance at ~€0.9 billion, lower end of the range.

Financial highlights

• Q3 2024 sales: €4,377M, down from €4,471M in Q3 2023; comparable sales growth flat year-over-year.

• Adjusted EBITA: €516M (11.8% margin), up from €456M (10.2%); adjusted EBITDA margin: 16.8% (up from 15.5%).

• Income from operations grew to €337M (7.7% of sales), up from €224M (5.0%).

• Adjusted diluted EPS from continuing operations was €0.32 in Q3, up 9% year-to-date.

• Operating cash flow was €192M, with ending cash balance at €1.5B.

Outlook and guidance

• Full-year 2024 comparable sales growth expected at 0.5–1.5% for the group, revised down due to China; outside China, growth expected at 3–5%.

• Adjusted EBITA/EBITDA margin expected around 11.5%, at the upper end of the range.

• Free cash flow guidance at ~€0.9B, lower end of the range, including €540M insurance receipt for Respironics recall, mostly in Q4.

• Segment outlook: Diagnosis & Treatment and Personal Health at lower end or flat, Connected Care at lower end of 3–5% range.

• Outlook excludes potential impact from ongoing Respironics legal proceedings.